Sorafenib decreases proliferation and induces apoptosis of prostate cancer cells by inhibition of the androgen receptor and Akt signaling pathways

Endocrine-Related Cancer

Volumn 19, Issue 3, 2012, Pages 305-319

  Oh, Su Jung ^a   Erb, Holger H H ^a   Hobisch, Alfred ^b   Santer, Frédéric R ^a   Culig, Zoran ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b General Hospital Feldkirch   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; BICALUTAMIDE; CYCLIN D1; CYCLIN DEPENDENT KINASE 2; DOCETAXEL; PROSTATE SPECIFIC ANTIGEN; PROTEIN KINASE B; PROTEIN MCL 1; SMALL INTERFERING RNA; SORAFENIB;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CASTRATION RESISTANT PROSTATE CANCER; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA SYNTHESIS; DOWN REGULATION; DRUG EFFICACY; ENZYME PHOSPHORYLATION; HUMAN; HUMAN TISSUE; PROSTATE CANCER; SIGNAL TRANSDUCTION;

ANDROGEN RECEPTOR ANTAGONISTS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZENESULFONATES; CASPASE 3; CASPASE 7; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN D1; CYCLIN-DEPENDENT KINASE 2; DOWN-REGULATION; HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-BCL-2; PYRIDINES; RECEPTORS, ANDROGEN; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION;

EID: 84862653140     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-11-0298     Document Type: Article

References (53)

1. Aragon-Ching JB, Jain L, Gulley JL, Arlen PM, Wright JJ, Steinberg SM, Draper D, Venitz J, Jones E, Chen CC et al. 2009 Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer. British Journal of Urology International 103 1636-1640. (doi:10.1111/j.1464- 410X.2008.08327.x)
2. Beardsley EK, Hotte SJ, North S, Ellard SL, Winquist E, Kollmannsberger C, Mukherjee SD & Chi KN 2012 A phase II study of sorafenib in combination with bicalutamide in patients with chemotherapy-naive castration resistant prostate cancer. Investigational New Drugs [in press].
3. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB Jr, Saad F et al. 2011 Abiraterone and increased survival in metastatic prostate cancer. New England Journal of Medicine 364 1995-2005. (doi:10.1056/NEJMoa1014618)
4. Cavarretta IT, Neuwirt H, Untergasser G, Moser PL, Zaki MH, Steiner H, Rumpold H, Fuchs D, Hobisch A, Nemeth JA et al. 2007 The antiapoptotic effect of IL-6 autocrine loop in a cellular model of advanced prostate cancer is mediated by Mcl-1. Oncogene 26 2822-2832. (doi:10.1038/sj.onc.1210097)
5. Chapuy B, Schuelper N, Panse M, Dohm A, Hand E, Schroers R, Truemper L & Wulff GG 2011 Multikinase inhibitor sorafenib exerts cytocidal efficacy against non-Hodgkin lymphomas associated with inhibition of MAPK14 and AKT phosphorylation. British Journal of Haematology 152 401-412. (doi:10.1111/j.1365-2141.2010.08526.x)
6. Chi KN, Ellard SL, Hotte SJ, Czaykowski P, Moore M, Ruether JD, Schell AJ, Taylor S, Hansen C, Gauthier I et al. 2008 A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer. Annals of Oncology 19 746-751. (doi:10.1093/annonc/mdm554)
7. Craft N, Shostak Y, Carey M & Sawyers CL 1999 A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nature Medicine 5 280-285. (doi:10.1038/6495)
8. Craig RW 2002 MCL1 provides a window on the role of the BCL2 family in cell proliferation, differentiation and tumorigenesis. Leukemia 16 444-454. (doi:10.1038/sj.leu.2402416)
9. Culig Z, Hoffmann J, Erdel M, Eder IE, Hobisch A, Hittmair A, Bartsch G, Utermann G, Schneider MR, Parczyk K et al. 1999 Switch from antagonist to agonist of the androgen receptor blocker bicalutamide is associated with prostate tumour progression in a new model system. British Journal of Cancer 81 242-251. (doi:10.1038/sj.bjc.6690684)
10. Culig Z, Steiner H, Bartsch G & Hobisch A 2005 Mechanisms of endocrine therapy-responsive and -unresponsive prostate tumours. Endocrine-Related Cancer 12 229-244. (doi:10.1677/erc.1.00775a)
11. Dahut WL, Scripture C, Posadas E, Jain L, Gulley JL, Arlen PM, Wright JJ, Yu Y, Cao L, Steinberg SM et al. 2008 A phase II clinical trial of sorafenib in androgen-independent prostate cancer. Clinical Cancer Research 14 209-214. (doi:10.1158/1078-0432.CCR-07-1355)
12. Desiniotis A, Schafer G, Klocker H & Eder IE 2010 Enhanced antiproliferative and proapoptotic effects on prostate cancer cells by simultaneously inhibiting androgen receptor and cAMP-dependent protein kinase A. International Journal of Cancer 126 775-789. (doi:10.1002/ijc.24806)
13. Ding Q, He X, Hsu JM, Xia W, Chen CT, Li LY, Lee DF, Liu JC, Zhong Q, Wang X et al. 2007 Degradation of Mcl-1 by beta-TrCP mediates glycogen synthase kinase 3-induced tumor suppression and chemosensitization. Molecular and Cellular Biology 27 4006-4017. (doi:10.1128/MCB.00620-06)
14. Feldman BJ & Feldman D 2001 The development of androgen-independent prostate cancer. Nature Reviews. Cancer 1 34-45. (doi:10.1038/35094009)
15. Gravis G, Bladou F, Salem N, Goncalves A, Esterni B, Walz J, Bagattini S, Marcy M, Brunelle S & Viens P 2008 Results from a monocentric phase II trial of erlotinib in patients with metastatic prostate cancer. Annals of Oncology 19 1624-1628. (doi:10.1093/annonc/mdn174)
16. Grossmann ME, Huang H & Tindall DJ 2001 Androgen receptor signaling in androgen-refractory prostate cancer. Journal of the National Cancer Institute 93 1687-1697. (doi:10.1093/jnci/93.22.1687)
17. Ha S, Ruoff R, Kahoud N, Franke TF & Logan SK 2011 Androgen receptor levels are upregulated by Akt in prostate cancer. Endocrine-Related Cancer 18 245-255. (doi:10.1530/ERC-10-0204)
18. Hobisch A, Ramoner R, Fuchs D, Godoy-Tundidor S, Bartsch G, Klocker H & Culig Z 2001 Prostate cancer cells (LNCaP) generated after long-term interleukin 6 (IL-6) treatment express IL-6 and acquire an IL-6 partially resistant phenotype. Clinical Cancer Research 7 2941-2948. (Pubitemid 32911405)
19. Hobisch A, Fritzer A, Comuzzi B, Fiechtl M, Malinowska K, Steiner H, Bartsch G & Culig Z 2006 The androgen receptor pathway is by-passed in prostate cancer cells generated after prolonged treatment with bicalutamide. Prostate 66 413-420. (doi:10.1002/pros.20365)
20. Huang S & Sinicrope FA 2010 Sorafenib inhibits STAT3 activation to enhance TRAIL-mediated apoptosis in human pancreatic cancer cells. Molecular Cancer Therapeutics 9 742-750. (doi:10.1158/1535-7163.MCT-09-1004)
21. Huang R, Chen XQ, Huang Y, Chen N & Zeng H 2010 The multikinase inhibitor sorafenib induces caspase-dependent apoptosis in PC-3 prostate cancer cells. Asian Journal of Andrology 12 527-534. (doi:10.1038/aja.2010.21)
22. Jemal A, Siegel R, Xu J & Ward E 2010 Cancer statistics, 2010. CA: A Cancer Journal for Clinicians 60 277-300. (doi:10.3322/caac.20073)
23. Kane RC, Farrell AT, Saber H, Tang S, Williams G, Jee JM, Liang C, Booth B, Chidambaram N, Morse D et al. 2006 Sorafenib for the treatment of advanced renal cell carcinoma. Clinical Cancer Research 12 7271-7278. (doi:10.1158/1078-0432.CCR-06-1249)
24. Kozopas KM, Yang T, Buchan HL, Zhou P & Craig RW 1993 MCL1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to BCL2. PNAS 90 3516-3520. (doi:10.1073/pnas.90.8.3516)
25. Krajewska M, Krajewski S, Epstein JI, Shabaik A, Sauvageot J, Song K, Kitada S & Reed JC 1996 Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers. American Journal of Pathology 148 1567-1576. (Pubitemid 26135897)
26. Kreisberg JI, Malik SN, Prihoda TJ, Bedolla RG, Troyer DA, Kreisberg S & Ghosh PM 2004 Phosphorylation of Akt (Ser473) is an excellent predictor of poor clinical outcome in prostate cancer. Cancer Research 64 5232-5236. (doi:10.1158/0008-5472.CAN-04-0272)
27. Lang L 2008 FDA approves sorafenib for patients with inoperable liver cancer. Gastroenterology 134 379. (Pubitemid 351173079)
28. Lian J, Ni Z, Dai X, Su C, Smith AR, Xu L & He F 2012 Sorafenib sensitizes (-)-gossypol-induced growth suppression in androgen-independent prostate cancer cells via Mcl-1 inhibition and Bak activation. Molecular Cancer Therapeutics 11 416-426. (doi:10.1158/1535-7163.MCT-11-0559)
29. Madan RA, Pal SK, Sartor O & Dahut WL 2011 Overcoming chemotherapy resistance in prostate cancer. Clinical Cancer Research 17 3892-3902. (doi:10.1158/1078-0432.CCR-10-2654)
30. Maurer U, Charvet C, Wagman AS, Dejardin E & Green DR 2006 Glycogen synthase kinase-3 regulates mitochondrial outer membrane permeabilization and apoptosis by destabilization of MCL-1. Molecular Cell 21 749-760. (doi:10.1016/j.molcel.2006.02.009)
31. Mellinghoff IK, Vivanco I, Kwon A, Tran C, Wongwipat J &Sawyers CL 2004 HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability. Cancer Cell 6 517-527. (doi:10.1016/j.ccr.2004.09.031)
32. Nesterov A, Lu X, Johnson M, Miller GJ, Ivashchenko Y &Kraft AS 2001 Elevated AKT activity protects the prostate cancer cell line LNCaP from TRAIL-induced apoptosis. Journal of Biological Chemistry 276 10767-10774. (doi:10.1074/jbc.M005196200)
33. Patterson SG, Wei S, Chen X, Sallman DA, Gilvary DL, Zhong B, Pow-Sang J, Yeatman T & Djeu JY 2006 Novel role of Stat1 in the development of docetaxel resistance in prostate tumor cells. Oncogene 25 6113-6122. (doi:10.1038/sj.onc.1209632)
34. Ploussard G, Terry S, Maille P, Allory Y, Sirab N, Kheuang L, Soyeux P, Nicolaiew N, Coppolani E, Paule B et al. 2010 Class III beta-tubulin expression predicts prostate tumor aggressiveness and patient response to docetaxel-based chemotherapy. Cancer Research 70 9253-9264. (doi:10.1158/0008-5472.CAN-10-1447)
35. Puhr M, Santer FR, Neuwirt H, Marcias G, Hobisch A &Culig Z 2010 SOCS-3 antagonises the proliferative and migratory effects of fibroblast growth factor-2 in prostate cancer by inhibition of p44/p42 MAPK signalling. Endocrine-Related Cancer 17 525-538. (doi:10.1677/ERC-10-0007)
36. Qian DZ, Rademacher BL, Pittsenbarger J, Huang CY, Myrthue A, Higano CS, Garzotto M, Nelson PS & Beer TM 2010 CCL2 is induced by chemotherapy and protects prostate cancer cells from docetaxel-induced cytotoxicity. Prostate 70 433-442.
37. Rahmani M, Davis EM, Bauer C, Dent P & Grant S 2005 Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation. Journal of Biological Chemistry 280 35217-35227. (doi:10.1074/jbc.M506551200)
38. Santer FR, Höschele PP, Oh SJ, Erb HH, Bouchal J, Cavarretta IT, Parson W, Meyers DJ, Cole PA & Culig Z 2011 Inhibition of the acetyltransferases p300 and CBP reveals a targetable function for p300 in the survival and invasion pathways of prostate cancer cell lines. Molecular Cancer Therapeutics 10 1644-1645. (doi:10.1158/1535-7163.MCT-11-0182)
39. Sircar K, Yoshimoto M, Monzon FA, Koumakpayi IH, Katz RL, Khanna A, Alvarez K, Chen G, Darnel AD, Aprikian AG et al. 2009 PTEN genomic deletion is associated with p-Akt and AR signalling in poorer outcome, hormone refractory prostate cancer. Journal of Pathology 218 505-513. (doi:10.1002/path.2559)
40. Sonpavde G, Hutson TE, Berry WR, Boehm KA & Asmar L 2008 Phase II trial of sunitinib for the therapy of progressive metastatic castration-refractory prostate cancer after previous docetaxel chemotherapy. Clinical Genitourinary Cancer 6 134-137. (doi:10.3816/CGC.2008.n.023)
41. Steinbild S, Mross K, Frost A, Morant R, Gillessen S, Dittrich C, Strumberg D, Hochhaus A, Hanauske AR, Edler L et al. 2007 A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research - EWIV. British Journal of Cancer 97 1480-1485. (doi:10.1038/sj.bjc. 6604064)
42. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I et al. 2004 Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. New England Journal of Medicine 351 1502-1512. (doi:10.1056/NEJMoa040720)
43. Tepper CG, Boucher DL, Ryan PE, Ma AH, Xia L, Lee LF, Pretlow TG & Kung HJ 2002 Characterization of a novel androgen receptor mutation in a relapsed CWR22 prostate cancer xenograft and cell line. Cancer Research 62 6606-6614. (Pubitemid 35364127)
44. Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, Wongvipat J, Smith-Jones PM, Yoo D, Kwon A et al. 2009 Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 324 787-790. (doi:10.1126/science.1168175)
45. Ullen A, Farnebo M, Thyrell L, Mahmoudi S, Kharaziha P, Lennartsson L, Grander D, Panaretakis T & Nilsson S 2010 Sorafenib induces apoptosis and autophagy in prostate cancer cells in vitro. International Journal of Oncology 37 15-20. (doi:10.3892/ijo-00000648)
46. Ulivi P, Arienti C, Zoli W, Scarsella M, Carloni S, Fabbri F, Tesei A, Chiadini E, Orlandi A, Passeri D et al. 2010 In vitro and in vivo antitumor efficacy of docetaxel and sorafenib combination in human pancreatic cancer cells. Current Cancer Drug Targets 10 600-610. (doi:10.2174/156800910791859489)
47. Visakorpi T, Hyytinen E, Koivisto P, Tanner M, Keinanen R, Palmberg C, Palotie A, Tammela T, Isola J & Kallioniemi OP 1995 In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nature Genetics 9 401-406. (doi:10.1038/ng0495-401)
48. Vlietstra RJ, van Alewijk DC, Hermans KG, van Steenbrugge GJ &Trapman J 1998 Frequent inactivation of PTEN in prostate cancer cell lines and xenografts. Cancer Research 58 2720-2723. (Pubitemid 28311897)
49. Wei G, Wang M, Hyslop T, Wang Z & Carr BI 2010 Vitamin K enhancement of sorafenib-mediated HCC cell growth inhibition in vitro and in vivo. International Journal of Cancer 127 2949-2958. (doi:10.1002/ijc.25498)
50. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M et al. 2004 BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Research 64 7099-7109. (doi:10.1158/0008-5472.CAN-04-1443)
51. Yadav A, Kumar B, Teknos TN & Kumar P 2011 Sorafenib enhances the antitumor effects of chemoradiation treatment by downregulating ERCC-1 and XRCC-1 DNA repair proteins. Molecular Cancer Therapeutics 10 1241-1251. (doi:10.1158/1535-7163.MCT-11-0004)
52. Yu C, Bruzek A, Meng XW, Gores GJ, Carter CA, Kaufmann SH & Adjei AA 2005 The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006. Oncogene 24 6861-6869. (doi:10.1038/sj.onc. 1208841)
53. Zemskova M, Sahakian E, Bashkirova S & Lilly M 2008 The PIM1 kinase is a critical component of a survival pathway activated by docetaxel and promotes survival of docetaxel-treated prostate cancer cells. Journal of Biological Chemistry 283 20635-20644. (doi:10.1074/jbc.M709479200)